|
【结 构 式】 
|
【分子编号】54595 【品名】tert-butyl(dimethyl)silyl (R)-(1-methyl-4,5-dihydro-1H-pyrazol-5-yl)(phenyl)methyl ether; 5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-1-methyl-4,5-dihydro-1H-pyrazole 【CA登记号】 |
【 分 子 式 】C17H28N2OSi 【 分 子 量 】304.5077 【元素组成】C 67.05% H 9.27% N 9.2% O 5.25% Si 9.22% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(R)-(VIII)Ethyl (R)-mandelate [(R)-IV] was protected as its tert-butyldimethylsilyl ether and reduced with DIBAL to [(R)-V], which was treated with ethoxycarbonylmethyl-enetriphenylphosphorane, followed by reduction to give [(R)-VI]. Subsequent oxidation to [(R)-VII] and cyclization by reaction with methylhydrazine afforded a mixture of pyrazolines [(R)-VIII]. Oxidation to pyrazole and deprotection yielded [(R)-(+)-I].
| 【1】 Farré, A.J.; Frigola, J.; Cizolirtine Citrate. Drugs Fut 2002, 27, 8, 721. |
| 【2】 Hueso, J.; Frigola, J.; Farré, A.; Berrocal, J.; Gutierrez, B.; Preparation of the enantiomers of the analgesic E-3710. Bioorg Med Chem Lett 1993, 3, 2, 269. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (R)-(+)-(I) | 54587 | (R)-(1-methyl-1H-pyrazol-5-yl)(phenyl)methanol | C11H12N2O | 详情 | 详情 | |
| (R)-(IV) | 54591 | ethyl (2R)-2-hydroxy-2-phenylethanoate | C10H12O3 | 详情 | 详情 | |
| (R)-(V) | 54592 | (2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-phenylethanal | C14H22O2Si | 详情 | 详情 | |
| (R)-(VI) | 54593 | (E,4S)-4-{[tert-butyl(dimethyl)silyl]oxy}-4-phenyl-2-buten-1-ol | C16H26O2Si | 详情 | 详情 | |
| (R)-(VII) | 54594 | (E,4S)-4-{[tert-butyl(dimethyl)silyl]oxy}-4-phenyl-2-butenal | C16H24O2Si | 详情 | 详情 | |
| (R)-(VIII) | 54595 | tert-butyl(dimethyl)silyl (R)-(1-methyl-4,5-dihydro-1H-pyrazol-5-yl)(phenyl)methyl ether; 5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]-1-methyl-4,5-dihydro-1H-pyrazole | C17H28N2OSi | 详情 | 详情 |
Extended Information